Arbutus Biopharma logo

ABUS - Arbutus Biopharma Share Price

$3.07 0.0  0.7%

Last Trade - 17/01/20

Sector
Healthcare
Size
Small Cap
Market Cap £146.6m
Enterprise Value £77.3m
Revenue £4.67m
Position in Universe 3859th / 6415
Bullish
Bearish
Unlock ABUS Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ABUS Revenue Unlock ABUS Revenue

Net Income

ABUS Net Income Unlock ABUS Revenue

Normalised EPS

ABUS Normalised EPS Unlock ABUS Revenue

PE Ratio Range

ABUS PE Ratio Range Unlock ABUS Revenue

Dividend Yield Range

ABUS Dividend Yield Range Unlock ABUS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ABUS EPS Forecasts Unlock ABUS Revenue
Profile Summary

Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline, the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development, which has enabled several clinical trials and has been administered to hundreds of human subjects.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated January 1, 2018
Public Since November 13, 2010
No. of Shareholders: 102
No. of Employees: 80
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 62,111,972
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ABUS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ABUS
Upcoming Events for ABUS
Similar to ABUS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.